The latest price target for Clearside Biomedical (NASDAQ:CLSD) was reported by Chardan Capital on October 14, 2024. The analyst firm set a price target for $6.00 expecting CLSD to rise to within 12 months (a possible 426.32% upside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for Clearside Biomedical (NASDAQ:CLSD) was provided by Chardan Capital, and Clearside Biomedical maintained their buy rating.

The last upgrade for Clearside Biomedical Inc happened on November 10, 2022 when Stifel raised their price target to $8. Stifel previously had a hold for Clearside Biomedical Inc.

There is no last downgrade for Clearside Biomedical.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Clearside Biomedical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Clearside Biomedical was filed on October 14, 2024 so you should expect the next rating to be made available sometime around October 14, 2025.

While ratings are subjective and will change, the latest Clearside Biomedical (CLSD) rating was a maintained with a price target of $6.00 to $6.00. The current price Clearside Biomedical (CLSD) is trading at is $1.14, which is out of the analyst’s predicted range.